Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of XXXX .

@entity1 @entity1261 @entity706 @entity5 @entity281 @entity1398 @entity2841 @entity1349
BACKGROUND: Granulopoiesis-stimulating factors ( @entity1261 and @entity2841 ) are being used to prevent @entity1398 and @entity281 in the treatment of @entity1 with @entity706 . The question whether @entity1261 and @entity2841 improve dose-intensity, @entity5 response and @entity1349 in this @entity1 population has not been answered yet. Since the results from single studies are inconclusive a systematic review was required. OBJECTIVES: To undertake a systematic review in @entity1 with @entity706 to determine the effectiveness of @entity1261 and @entity2841 to prevent @entity1398 , @entity1398 , @entity281 , improve quality of life, adherence to the treatment protocol, @entity5 response, freedom from treatment failure (FFTF), @entity1349 ( @entity1349 ) and to assess adverse events of @entity1261 and @entity2841 . SEARCH STRATEGY: Medline, Embase, CancerLit, the Cochrane Library and smaller databases, Internet-databases of ongoing trials, conference proceedings of the American Society of Clinical Oncology and the American Society of Hematology were searched. We included full-text and abstract publications as well as unpublished data. SELECTION CRITERIA: Randomised controlled trials comparing prophylaxis with @entity1261 or @entity2841 versus placebo/no prophylaxis in adult @entity1 with @entity706 undergoing chemotherapy were included in this review. Both study arms had to receive identical chemotherapy and supportive care. DATA COLLECTION AND ANALYSIS: Eligibility and quality assessment, data extraction and analysis were done in duplicate. Authors were contacted to obtain missing data. MAIN RESULTS: We included 12 eligible studies with 1.823 randomised @entity1 . Compared with no prophylaxis, G-/ @entity2841 significantly reduced the relative risk for severe @entity1398 (RR 0.67 [95% CI 0.60-0.73]), @entity1398 (RR 0.74 [95% CI 0.62-0.89]) and @entity281 (RR 0.74 [95% CI 0.64-0.85]). There was no evidence for G-/ @entity2841 to decrease the number of @entity1 who required iv antibiotics (RR 0.82 [95%CI 0.57-1.18]), to reduce @entity281 related mortality (RR 1.37 [95% CI 0.66-2.82]), or to improve complete @entity5 response (RR 1.02 [95% CI 0.94-1.11]), FFTF (HR 1.11 [95% CI 0.91-1.35]) and @entity1349 (HR 1.00 [95% CI 0.86-1.16]). One study evaluated quality of life parameters and did not find differences between the groups. REVIEWER'S CONCLUSIONS: @entity1261 and @entity2841 , when given prophylactically in @entity1 with @entity706 undergoing conventional chemotherapy, reduce the risk of @entity1398 , @entity1398 and @entity281 . However, based on the currently available randomised trials in this clinical setting, there is no evidence for G-/ @entity2841 to provide a significant advantage in terms of complete @entity5 response, FFTF and @entity1349 .
